Recruitment

Recruitment Status
Completed

Inclusion Criterias

previously randomised in study TH002, completed all dosing visits and the PTC
previously randomised in study TH002, completed all dosing visits and the PTC

Exclusion Criterias

"Partly controlled" and "uncontrolled" asthma
History of anaphylaxis to House Dust Mite allergen
Subjects who cannot tolerate allergen challenge in the EEC
...
"Partly controlled" and "uncontrolled" asthma
History of anaphylaxis to House Dust Mite allergen
Subjects who cannot tolerate allergen challenge in the EEC
Symptoms of a clinically relevant illness
FEV1 <80% of predicted.

Summary

Conditions
  • House Dust Mite Allergy
  • Rhinoconjunctivitis
Type
Observational
Design
  • Observational Model: Cohort
  • Time Perspective: Prospective

Participation Requirements

Age
Between 18 years and 64 years
Gender
Both males and females

Description

Subjects who completed all dosing visits and the post treatment challenge (PTC) in study TH002 will be invited to attend the Screening visit for TH002a. Subjects will attend for 3 visits to the EEU on successive days. Following the last EEC visit a follow-up visit will be performed 3-10 days later.

Subjects who completed all dosing visits and the post treatment challenge (PTC) in study TH002 will be invited to attend the Screening visit for TH002a. Subjects will attend for 3 visits to the EEU on successive days. Following the last EEC visit a follow-up visit will be performed 3-10 days later.

Inclusion Criterias

previously randomised in study TH002, completed all dosing visits and the PTC
previously randomised in study TH002, completed all dosing visits and the PTC

Exclusion Criterias

"Partly controlled" and "uncontrolled" asthma
History of anaphylaxis to House Dust Mite allergen
Subjects who cannot tolerate allergen challenge in the EEC
...
"Partly controlled" and "uncontrolled" asthma
History of anaphylaxis to House Dust Mite allergen
Subjects who cannot tolerate allergen challenge in the EEC
Symptoms of a clinically relevant illness
FEV1 <80% of predicted.

Tracking Information

NCT #
NCT01923792
Collaborators
  • Adiga Life Sciences, Inc.
  • Inflamax Research Incorporated
Investigators
Not Provided